AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday.

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the US prepares to get its booster campaign underway.

Pfizer said Friday that the Food and Drug Administration approved its treatment for patients with metastatic colorectal cancer. The FDA approved braftovi in combination with cetuximab and mFolfox6 ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination ...

People with hemophilia A or B got two new treatments: Pfizer’s Hympavzi (marstacimab) and Novo Nordisk’s Alhemo (concizumab). The FDA also gave ... drug to be approved in decades.

For the 43rd edition of the JPM conference, Johnson & Johnson stole the spotlight off the bat, announcing a $14.6 billion acquisition of Intra-Cellular Therapies and its FDA-approved drug Caplyta ...

A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.

On Monday, Sangamo Therapeutics ... including seeking a potential new collaboration partner. Also Read: FDA Approves Pfizer’s Second Hemophilia Drug With Six Months In July 2024, Pfizer ...